Widegren Henrik, Andersson Morgan, Greiff Lennart
Department of Otorhinolaryngology, Head & Neck Surgery, Lund University Hospital, Lund, Sweden.
Ann Allergy Asthma Immunol. 2009 Jan;102(1):51-6. doi: 10.1016/S1081-1206(10)60108-1.
The Clara cell 10 (CC10) protein is produced by the airway epithelium. Reduced levels of CC10 are associated with allergic rhinitis and asthma. In experimental models, treatment with the CC10 protein may reduce features of airway inflammation.
To examine whether or not topical treatment with recombinant human CC10 (rhCC10) affects symptoms and signs of allergic rhinitis in a pollen season model.
Out of the pollen season, patients with allergic rhinitis received treatment with rhCC10, 0.56 mg per nasal cavity, once daily for 7 days in a double-blinded, placebo-controlled, crossover design. During this period, individualized allergen challenges were given once daily. Symptoms and peak nasal inspiratory flow (PNIF) were recorded daily in the morning, 10 minutes after challenge, and in the evening. Mean recordings of the last 3 days of the challenge series were used in the analysis. Nasal lavages were performed at the end of each challenge period, and eosinophil cationic protein, myeloperoxidase, and alpha2-macroglobulin levels were measured as indices of eosinophil and neutrophil activity and plasma exudation, respectively.
Recombinant human CC10 did not affect allergen-induced morning, postchallenge, or evening symptoms compared with placebo. Morning, postchallenge, and evening PNIF were not improved by rhCC10. No statistically significant differences were observed between rhCC10 and placebo for any of the lavage fluid indices.
Repeated nasal administrations of rhCC10 protein, in the present dose, do not exert antiallergic effects in seasonal allergic rhinitis.
克拉拉细胞10（CC10）蛋白由气道上皮产生。CC10水平降低与过敏性鼻炎和哮喘相关。在实验模型中，用CC10蛋白治疗可能减轻气道炎症特征。
在花粉季节模型中，研究重组人CC10（rhCC10）局部治疗是否影响过敏性鼻炎的症状和体征。
在花粉季节之外，过敏性鼻炎患者采用双盲、安慰剂对照、交叉设计，接受rhCC10治疗，每侧鼻腔0.56mg，每日一次，共7天。在此期间，每天进行一次个体化变应原激发试验。每天早晨、激发试验后10分钟和晚上记录症状和鼻吸气峰流速（PNIF）。分析采用激发试验系列最后3天的平均记录。每个激发试验期结束时进行鼻腔灌洗，分别测定嗜酸性粒细胞阳离子蛋白、髓过氧化物酶和α2-巨球蛋白水平，作为嗜酸性粒细胞和中性粒细胞活性及血浆渗出的指标。
与安慰剂相比，重组人CC10不影响变应原诱发的早晨、激发试验后或晚上症状。rhCC10未改善早晨、激发试验后和晚上的PNIF。rhCC10与安慰剂在任何灌洗液指标上均未观察到统计学显著差异。
以目前剂量反复经鼻给予rhCC10蛋白对季节性过敏性鼻炎无抗过敏作用。
